



NEWS RELEASE

## Hologic Announces Completion of Loan Repricing

3/20/2013

Interest rates on Term Loan A and Revolving Credit Facility reduced by 100 basis points

BEDFORD, Mass., March 20, 2013 /PRNewswire/ -- Hologic, Inc. (Hologic or the Company) (NASDAQ: HOLX), a leading developer, manufacturer and supplier of premium diagnostics products, medical imaging systems and surgical products dedicated to serving the healthcare needs of women, announced today that the Company completed a repricing of certain loans under the Company's Credit and Guaranty Agreement (Credit Agreement) dated August 1, 2012.

On March 20, 2013, the Company and several of its domestic subsidiaries (Guarantors), together with Goldman Sachs Bank USA, as administrative and collateral agent, and the lenders party thereto entered into Refinancing Amendment No. 1 (Credit Agreement Amendment).

The Credit Agreement Amendment refinances the Company's existing senior secured tranche A term loan facility (Term Loan A) and the Company's existing \$300 million senior secured revolving credit facility (Revolving Facility), each with a maturity date of August 1, 2017, resulting in a 100 basis points reduction in the interest rates (from 3.00% plus LIBOR to 2.00% plus LIBOR) on the Term Loan A and the Revolving Facility. In addition, certain covenants and terms of the Credit Agreement were amended. As of March 20, 2013, the principal amounts outstanding on the Term Loan A and Revolving Facility were approximately \$975 million and \$0, respectively.

Effective today, amounts outstanding under the Term Loan A and the Revolving Facility initially bear interest, at the Company's option, at: (i) the Base Rate (as defined in the Credit Agreement) plus 1.00% per annum or (ii) the Adjusted Eurodollar Rate/LIBOR plus 2.00% per annum. The applicable margin with respect to the Term Loan A and Revolving Facility are subject to specified changes depending on the total net leverage ratio, as defined in the Credit Agreement.

About Hologic, Inc.

Hologic, Inc. is a leading developer, manufacturer and supplier of premium diagnostic products, medical imaging systems, and surgical products. The Company operates four core business units focused on diagnostics, breast health, GYN surgical and skeletal health. With a comprehensive suite of technologies and a robust research and development program, Hologic is committed to improving lives. The Company is headquartered in Massachusetts. For more information, visit [www.hologic.com](http://www.hologic.com).

Hologic and associated logos are trademarks and/or registered trademarks of Hologic, Inc. and/or its subsidiaries in the United States and/or other countries.

---

Contacts:

Deborah Gordon  
Vice President, Investor Relations  
(781) 999-7716  
[deborah.gordon@hologic.com](mailto:deborah.gordon@hologic.com)

Al Kildani  
Senior Director, Investor Relations  
(858) 410-8653  
[al.kildani@hologic.com](mailto:al.kildani@hologic.com)

David Cross  
Vice President & Treasurer  
(781) 999-7789  
[david.cross@hologic.com](mailto:david.cross@hologic.com)

SOURCE Hologic, Inc.